ORKAMBIHCP.COM: Keyword Density Checker

Total words: 4064 | 2-word phrases: 1030 | 3-word phrases: 1229 | 4-word phrases: 1312

PAGE INFO

Title	Try to keep the title under 60 characters (59 characters) ORKAMBI® (lumacaftor/ivacaftor) \| Healthcare Professionals
Description	Try to keep the meta description between 50 - 160 characters (187 characters) Learn about ORKAMBI, including clinical information, safety profile, dosing and administration, and mechanism of action. See Important Safety Information and full Prescribing Information.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (101 characters) FOR PEOPLE WITH CYSTIC FIBROSIS AS YOUNG AS 1 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508del MUTATION1-4

#	Keyword	Frequency	Density
1	patients treated with orkambi	13	0.99%
2	homozygous for the f508del	11	0.84%
3	from an openlabel trial	9	0.69%
4	was similar to that	9	0.69%
5	years from an openlabel	9	0.69%
6	cystic fibrosis homozygous for	9	0.69%
7	patients with advanced liver	8	0.61%
8	for the f508del mutation	8	0.61%
9	in patients with cf	8	0.61%
10	with advanced liver disease	7	0.53%
11	trials 1 and 2	7	0.53%
12	in patients with advanced	7	0.53%
13	have been reported in	7	0.53%
14	consider the benefits and	6	0.46%
15	≥5 of patients treated	6	0.46%
16	in ≥5 of patients	6	0.46%
17	children aged 25 years	6	0.46%
18	fibrosis homozygous for f508delcftr	6	0.46%
19	in trials 1 and	6	0.46%
20	interrupted in patients with	6	0.46%
21	2 years and older	6	0.46%
22	with cystic fibrosis homozygous	6	0.46%
23	the benefits and risks	6	0.46%
24	that in patients aged	6	0.46%
25	similar to that in	6	0.46%
26	in patients age 1	6	0.46%
27	to that in patients	6	0.46%
28	an openlabel trial trial	6	0.46%
29	of lumacaftor and ivacaftor	6	0.46%
30	study lancet respir med	6	0.46%
31	of patients treated with	5	0.38%
32	alt ast or bilirubin	5	0.38%
33	patients with alt or	4	0.30%
34	in patients with alt	4	0.30%
35	are homozygous for the	4	0.30%
36	should be closely monitored	4	0.30%
37	with alt or ast	4	0.30%
38	most common adverse reactions	4	0.30%
39	upper and sputum increased	3	0.23%
40	and sputum increased the	3	0.23%

#	URL	Whois	Check
1	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
2	https://www.ORKAMBI.com	Whois	ORKAMBI.com
3	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
4	https://www.vertextreatmentshcp.com	Whois	vertextreatmentshcp.com
5	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
6	https://www.ORKAMBI.com	Whois	ORKAMBI.com
7	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
8	https://www.orkambi.com/	Whois	orkambi.com
9	https://www.vertextreatmentshcp.com/	Whois	vertextreatmentshcp.com
10	https://www.vertextreatmentshcp.com	Whois	vertextreatmentshcp.com
11	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
12	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
13	https://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf	Whois	vrtx.com
14	https://www.vrtx.com/	Whois	vrtx.com
15	https://www.vrtx.com/our-company	Whois	vrtx.com
16	https://www.vrtx.com/english-privacy-us-residents	Whois	vrtx.com
17	https://www.vrtx.com/terms-and-conditions	Whois	vrtx.com
18	https://www.vrtx.com/contact-us	Whois	vrtx.com
19	https://www.vertexgps.com/how-to-enroll-patients	Whois	vertexgps.com
20	https://www.vrtx.com/	Whois	vrtx.com